Other Posts
Tecentriq (atezolizumab) / Roche
Tecentriq: Regulatory submission in Japan for ovarian cancer in 2020 (Chugai) - Oct 22, 2020 - Q3 2020 Results: Regulatory submission in Japan for early breast cancer in 2021
Keytruda (pembrolizumab)/ Merck (MSD); BI-1808 / BioInvent
CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial (PRNewswire)- Oct 26, 2020 - "BioInvent International AB...announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...The study will explore the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent and in combination with Keytruda® in patients with ovarian cancer, non-small cell lung cancer and CTCL....The Phase II a will consist of expansion cohorts to assess signs of efficacy of BI-1808 as single agent and in combination with Keytruda® in lung cancer and ovarian cancer patients. A separate cohort will explore the activity as single agent in CTCL (Sézarysyndrome and mycosis fungoides)."
Zejula (niraparib)/ GSK, ZAI Lab, J&J, Takeda
A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea (clinicaltrials.gov) - Oct 19, 2020 - P; N=600;Recruiting; Sponsor: Takeda
tisotumabvedotin (HuMax-TF-ADC) / Genmab, Seagen
A Studyof Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (clinicaltrials.gov)- Oct 22, 2020 - P2; N=222; Recruiting; Sponsor: Seattle Genetics, Inc.; N=122--> 222
mirvetuximabsoravtansine (IMGN 853) / ImmunoGen, Huadong Medicine
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China (Businesswire) - Oct 19, 2020 - “ImmunoGen,Inc…and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan(Greater China). ImmunoGen will retain all rights to mirvetuximab in the rest of the world…’We look forward to working closely with Huadong Medicine to develop and commercialize mirvetuximab in Greater China as we advance the mirvetuximabprogram and prepare for the first potential commercial launch in the United States in 2022’…Under the terms of the agreement, ImmunoGen will receive an upfront payment of $40 million and is eligible to receive additional milestone payments of up to $265 million as certain development, regulatory, and commercial objectives are achieved.”
REGN4018/ Regeneron, Sanofi; Libtayo (cemiplimab) / Sanofi, Regeneron
Study ofREGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. (clinicaltrials.gov)- Oct 19, 2020 - P1/2; N=290; Not yet recruiting; Sponsor: Regeneron Pharmaceuticals
Lynparza(olaparib) / Merck (MSD), AstraZeneca
RETROLA: Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients (clinicaltrials.gov) - Oct 19, 2020 - P=N/A;N=130; Completed; Sponsor: ARCAGY/ GINECO GROUP; Active, not recruiting -->Completed
